人福医药(600079.SH)：重酒石酸去甲肾上腺素注射液获得药品注册证书

Core Viewpoint - The approval of the drug registration certificate for heavy tartrate norepinephrine injection by the National Medical Products Administration marks a significant milestone for the company, allowing it to sell the product in the domestic market and enhancing its product line [1] Group 1 - The company’s subsidiary, Yichang Renfu Pharmaceutical Co., Ltd., holds 80% of the shares and has received the drug registration certificate [1] - The approval signifies the company’s qualification to market the drug in China, which is expected to have a positive impact on its business [1] - The addition of this product to the company's portfolio will further enrich its offerings in the pharmaceutical market [1]